291 related articles for article (PubMed ID: 16554855)
21. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy.
Alessandro S; Vincenzo G; Maria AG; Stefano S; Alessandro G; Salvatore M; Vincenzo T; Franco DS
Endocr Relat Cancer; 2007 Sep; 14(3):625-32. PubMed ID: 17914093
[TBL] [Abstract][Full Text] [Related]
22. [Testicular metastasis of prostatic carcinoma: report of a case].
Picurelli L; Terradez J; Sendra A; Baixauli J; Fernández A; Alcala-Santaella C; Tramoyeres A
Actas Urol Esp; 1994 Apr; 18(4):319-20. PubMed ID: 7976723
[TBL] [Abstract][Full Text] [Related]
23. Captopril may reduce biochemical (prostate-specific antigen) failure following radical prostatectomy for clinically localized prostate cancer.
Ronquist G; Frithz G; Wang YH; Lindeborg T
Scand J Urol Nephrol; 2009; 43(1):32-6. PubMed ID: 18932051
[TBL] [Abstract][Full Text] [Related]
24. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy.
Choueiri TK; Dreicer R; Paciorek A; Carroll PR; Konety B
J Urol; 2008 Mar; 179(3):906-10; discussion 910. PubMed ID: 18207194
[TBL] [Abstract][Full Text] [Related]
25. Successful salvage robotic-assisted radical prostatectomy after external beam radiotherapy failure.
Jamal K; Challacombe B; Elhage O; Popert R; Kirby R; Dasgupta P
Urology; 2008 Dec; 72(6):1356-8. PubMed ID: 18533232
[TBL] [Abstract][Full Text] [Related]
26. Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases.
Osunkoya AO; Nielsen ME; Epstein JI
Am J Surg Pathol; 2008 Mar; 32(3):468-72. PubMed ID: 18300802
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy.
Huang SP; Huang CY; Wang JS; Liu CC; Pu YS; Yu HJ; Yu CC; Wu TT; Huang CH; Wu WJ; Chou YH; Wu MT
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6632-8. PubMed ID: 18006764
[TBL] [Abstract][Full Text] [Related]
28. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system.
Buskirk SJ; Pisansky TM; Schild SE; Macdonald OK; Wehle MJ; Kozelsky TF; Collie AC; Ferrigni RG; Myers RP; Prussak KA; Heckman MG; Crook JE; Parker AS; Igel TC
J Urol; 2006 Sep; 176(3):985-90. PubMed ID: 16890677
[TBL] [Abstract][Full Text] [Related]
29. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
[TBL] [Abstract][Full Text] [Related]
30. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database.
Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
J Urol; 2009 Nov; 182(5):2250-5. PubMed ID: 19758614
[TBL] [Abstract][Full Text] [Related]
31. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality.
Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Dorey FJ; Walsh PC; Partin AW
J Clin Oncol; 2007 May; 25(13):1765-71. PubMed ID: 17470867
[TBL] [Abstract][Full Text] [Related]
32. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M
Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491
[TBL] [Abstract][Full Text] [Related]
33. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
Nieder AM; Porter MP; Soloway MS
J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
[TBL] [Abstract][Full Text] [Related]
34. Zonal origin of localized prostate cancer does not affect the rate of biochemical recurrence after radical prostatectomy.
Chun FK; Briganti A; Jeldres C; Erbersdobler A; Schlomm T; Steuber T; Gallina A; Walz J; Perrotte P; Huland H; Graefen M; Karakiewicz PI
Eur Urol; 2007 Apr; 51(4):949-55; discussion 955. PubMed ID: 16904818
[TBL] [Abstract][Full Text] [Related]
35. [A case of papillary adenocarcinoma of the prostate].
Kurokawa T; Kato N; Morikawa S; Kanai S
Hinyokika Kiyo; 2003 Jul; 49(7):415-7. PubMed ID: 12968485
[TBL] [Abstract][Full Text] [Related]
36. Incidentally discovered capillary hemangioma of the prostate.
Ristau BT; Tomaszewski JJ; Parwani AV; Ost MC
Can J Urol; 2011 Oct; 18(5):5914-5. PubMed ID: 22018156
[TBL] [Abstract][Full Text] [Related]
37. Testicular metastasis from carcinoma of prostate: report of two cases.
Deb P; Chander Y; Rai RS
Prostate Cancer Prostatic Dis; 2007; 10(2):202-4. PubMed ID: 17224911
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
Pruthi RS; Derksen JE; Moore D; Carson CC; Grigson G; Watkins C; Wallen E
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2172-7. PubMed ID: 16609031
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific antigen doubling time is a reliable predictor of imageable metastases in men with biochemical recurrence after radical retropubic prostatectomy.
Perlmutter MA; Lepor H
Urology; 2008 Mar; 71(3):501-5. PubMed ID: 18342197
[TBL] [Abstract][Full Text] [Related]
40. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
